RecruitingHepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Sponsor: AstraZeneca
Where it's recruiting
California
La Jolla · Los Angeles
Maryland
Baltimore
Massachusetts
Boston
Missouri
St Louis
New Jersey
Hackensack
Texas
Houston
Source: ClinicalTrials.gov · NCT06795022 · last updated 2026-08-13